This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Adler, L. A. Articles by Michelson, D. PubMed PubMed Citation Articles by Adler, L. A. Articles by Michelson, D. Social Bookmarking                   What's this?

Long-Term, Open-Label Safety and Efficacy of Atomoxetine in Adults With ADHD: Final Report of a 4-Year Study

^* To whom correspondence should be addressed. E-mail: lenard.adler{at}med.nyu.edu.

	Abstract

Objective: Previously, data from 97 weeks of open-label atomoxetine treatment of adults with attention-deficit/hyperactivity disorder (ADHD) were reported. This final report of that study presents results from over 4 years of treatment. Method: Results were derived from the study of 384 patients (125 patients remaining in the open-label trial since the interim report), receiving up to 221 weeks of treatment. Primary efficacy measure was the Conners’ Adult ADHD Rating Scale–Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom score. Adverse events and vital signs were assessed. Results: CAARS-Inv:SV Total ADHD Symptom scores decreased 30.2% (p < .001) during treatment. Similar, significant decreases were noted for the secondary efficacy measures, including the Sheehan Disability Scale Total score, which improved 25.3% (p < .001). Adverse events consisted primarily of pharmacologically (noradrenergic) expected effects. Conclusions: Results of this open-label study support the long-term efficacy, safety, and tolerability of atomoxetine for the treatment of adult ADHD. (J. of Att. Dis. 2008; XX(X) xx-xx)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?